Cabozantinib

Mar 04, 2020

$770M Thyroid Cancer Drugs Market Insights, 2015-2030

Dec 30, 2019

Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer

Oct 15, 2019

Health Canada Approves Ipsen's CABOMETYX(TM) (cabozantinib) for the First-Line Treatment of Adults with Advanced Renal Cell Carcinoma

Sep 29, 2019

Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers

Jun 27, 2019

CB-839 (Calithera Biosciences) Drug Overview 2019: CB-839 will be the First Glutaminase Inhibitor Approved for the Treatment of Renal Cell Carcinoma

Sep 19, 2018

Health Canada Approves Ipsen's CABOMETYX(TM) (cabozantinib) Giving Physicians and Patients a Novel Second-Line Option in the Fight Against Advanced Renal Cell Carcinoma

Feb 13, 2018

Cabozantinib shows significant activity in the first line for differentiated thyroid cancer

Jan 15, 2018

Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX®

Jun 21, 2017

Biopharma Stock Breakouts With Significant Developments and Market Activity